SUBSCRIBE

BOD Australia Ltd  ASX:BDA

Company

Current Price

First Coverage

Date

Price

5 Day VWAP

VWAP Returns

Our Entry Price

Our Returns

$ 0.310

17-Mar-21

$ 0.485

$ 0.534

-42%

$ 0.500

-38%

Report Date Price Current Return
BDA is a Medicinal Cannabis Stock with Growing Global Revenues 17-Mar-21 $0.485 -36%
Overlooked ASX Cannabis Stock with a Global Revenue Footprint 17-Mar-21 $0.485 -36%
More US Sales Expected. BDA Fully Funded for Manufacturing Requirements 08-Apr-21 $0.495 -37%
How Our Investments Performed in Q1 of 2021 21-Apr-21 $0.490 -37%
BDA Records Highest Ever Monthly Sales of Medical Cannabis Products 10-May-21 $0.420 -26%
FYI and BDA in the news 18-Jun-21 $0.360 -14%
BDA achieves record FY21 – so why is the share price down? 16-Jul-21 $0.330 -6%
BDA posts record breaking full year revenue, up 25% 26-Aug-21 $0.285 9%
ASX:BDA Cannabidiol (Cannabis) Product to Treat Insomnia 22-Sep-21 $0.275 13%

ASX:BDA

Our Current Returns

-38%

Current Price

$ 0.310

First Coverage

17-Mar-21

$ 0.485

5 Day VWAP

$ 0.534

VWAP Returns

-42%

Our Entry Price

$ 0.500

Our Current Returns

-38%

Past Coverage
BDA is a Medicinal Cannabis Stock with Growing Global Revenues
Overlooked ASX Cannabis Stock with a Global Revenue Footprint
More US Sales Expected. BDA Fully Funded for Manufacturing Requirements
How Our Investments Performed in Q1 of 2021
BDA Records Highest Ever Monthly Sales of Medical Cannabis Products
FYI and BDA in the news
BDA achieves record FY21 – so why is the share price down?
BDA posts record breaking full year revenue, up 25%
ASX:BDA Cannabidiol (Cannabis) Product to Treat Insomnia

Overview

📋 About: BDA is an Australian medicinal cannabis, Cannabidiol (CBD) and hemp healthcare company that delivers premium, proven and trusted products for both the consumer and medicinal markets. 

🌏  Macro Theme: The past six months has seen a large global regulatory shift with regards to cannabis classification. In Australia, the Therapeutic Goods Administration (TGA) announced a decision to down schedule CBD products to Schedule 3 (Pharmacist Only) medicines.

Additionally, a decision from the United Nations Commission on Narcotic Drugs accepted a recommendation from the World Health Organisation to remove cannabis and its derivatives from Schedule IV of the Single Convention on Narcotic Drugs.

BOD Australia Company Milestones

Portfolio Initiation: Wise-Owl Commentary
✅ US Market Entry, Purchase Order 1 (US): Wise-Owl Commentary
🔲 Additional Purchase Order 2 (US)
🔲 Additional Purchase Order 3 (US)
✅ MediCabilis™ UK Expansion: Wise-Owl Commentary
✅ Major Online Retailers Stock CBII Products: Wise-Owl Commentary
✅ MediCabilis™ 10,000 Annual Prescriptions: Wise-Owl Commentary
🔲 MediCabilis™ 25,000 Annual Prescriptions (FY 22)
🔲 MediCabilis™ 50,000 Annual Prescriptions (FY 23)
🔲 Additional Purchase Order 1 (Europe)
🔲 Additional Purchase Order 2 (Europe)
🔲 Additional Purchase Order 1 (UK)
🔲 Additional Purchase Order 2 (UK)
✅ $5M+ Annual Revenue
🔲 Revenue Growth (July-Sep Quarter)
🔲 Revenue Growth (Oct-Dec Quarter)
🔲 Cash Flow Positive (Half Year)
🔲 Cash Flow Positive (Full Year)
🔲 New Market Entry 1
🔲 New Market Entry 2
🔲 Unexpected Positive Announcement 1
🔲 Unexpected Positive Announcement 2
🔲 Unexpected Positive Announcement 3

Research & Development

Insomnia Study

Partnership with Woodcock Institute of Medical Research
✅ Phase IIB Trial Design Finalised
🔲 Ethics Approval for Study
🔲 Patient Recruitment Commenced
🔲 Phase IIB Trials
🔲 Phase IIB Trial Results
🔲 Submission of data to TGA
🔲 Product Registered
🔲 Product Licence / Commercialised

Long COVID Study

✅ Collaboration Agreement for Long-COVID Study (Drug Science)
🔲 Ethics Approval for Long-COVID Study
🔲 Long-COVID Study Commenced
🔲 Positive Outcome from Long-COVID Study
🔲 New Product Development 2
🔲 New Product Development 3

Wise-Owl Investment Milestones

✅ Initial Investment: @50.5c
🔲 Increase Investment 1
🔲 Increase Investment 2
🔲 Price increases 250% from initial entry
🔲 Price increases 500% from initial entry
🔲 Price increases 1000% from initial entry
🔲 12 Month Capital Gain Discount
🔲 Free Carry
🔲 Take Some Profit
🔲 Hold remaining Position for next 2+ years

”Expected Company Milestones” are based on the company’s publicly available execution plan and some assumptions made by our team on potential announcements that should de-risk the investment. “Our investment milestones” show our current long-term investment plan. Early stage investments are risky and there is no guarantee that the expected events will occur. The lists are not in sequential order.

Key

🔲 Expected Milestone
✅ Achieved Milestone
🟥 Negative Result
🌎 Macro Event

Why We Invested

Icon
Relationship with Health and Happiness Group
Icon
International expansion currently underway
Icon
Regulations opening up across the globe
Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere